Barclays’s China Biologic Products Holdings, Inc. CBPO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-9,892
| Closed | -$1.17M | – | 5221 |
|
|
2021
Q1 | $1.17M | Buy |
9,892
+9,655
| +4,074% | +$1.14M | ﹤0.01% | 2678 |
|
|
2020
Q4 | $28K | Sell |
237
-14,251
| -98% | -$1.66M | ﹤0.01% | 4615 |
|
|
2020
Q3 | $1.61M | Buy |
14,488
+3,871
| +36% | +$416K | ﹤0.01% | 2286 |
|
|
2020
Q2 | $1.08M | Buy |
10,617
+10,594
| +46,061% | +$1.13M | ﹤0.01% | 2681 |
|
|
2020
Q1 | $2K | Sell |
23
-8,107
| -100% | -$932K | ﹤0.01% | 6058 |
|
|
2019
Q4 | $947K | Sell |
8,130
-691
| -8% | -$80K | ﹤0.01% | 3728 |
|
|
2019
Q3 | $1.01M | Sell |
8,821
-881
| -9% | -$87.6K | ﹤0.01% | 3659 |
|
|
2019
Q2 | $924K | Buy |
9,702
+8,462
| +682% | +$797K | ﹤0.01% | 3758 |
|
|
2019
Q1 | $113K | Sell |
1,240
-3,213
| -72% | -$263K | ﹤0.01% | 5265 |
|
|
2018
Q4 | $339K | Buy |
4,453
+2,451
| +122% | +$180K | ﹤0.01% | 4177 |
|
|
2018
Q3 | $159K | Sell |
2,002
-145
| -7% | -$13.5K | ﹤0.01% | 5182 |
|
|
2018
Q2 | $213K | Sell |
2,147
-591
| -22% | -$51.1K | ﹤0.01% | 4673 |
|
|
2018
Q1 | $222K | Buy |
2,738
+493
| +22% | +$39.9K | ﹤0.01% | 4750 |
|
|
2017
Q4 | $176K | Sell |
2,245
-1,567
| -41% | -$130K | ﹤0.01% | 4789 |
|
|
2017
Q3 | $352K | Buy |
3,812
+3,444
| +936% | +$331K | ﹤0.01% | 3938 |
|
|
2017
Q2 | $42K | Buy |
368
+205
| +126% | +$22.9K | ﹤0.01% | 5459 |
|
|
2017
Q1 | $17K | Sell |
163
-667
| -80% | -$71.3K | ﹤0.01% | 5886 |
|
|
2016
Q4 | $89K | Buy |
+830
| New | +$97K | ﹤0.01% | 4833 |
|
|
2016
Q3 | – | Sell |
-417
| Closed | -$44K | – | 6963 |
|
|
2016
Q2 | $44K | Buy |
417
+224
| +116% | +$26K | ﹤0.01% | 4897 |
|
|
2016
Q1 | $22K | Sell |
193
-282
| -59% | -$33.1K | ﹤0.01% | 5184 |
|
|
2015
Q4 | $67K | Buy |
+475
| New | +$54.8K | ﹤0.01% | 4641 |
|
Barclays's CBPO Position: Q2 2021 in Review
Barclays sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2021, closing a stake of 9,892 shares — an estimated $1.17M sold.
Barclays first reported a position in CBPO in Q4 2015 and held it in 21 quarters. The position peaked at $1.61M in Q3 2020. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.
- Barclays reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2021 after selling out during the quarter.
- Barclays sold 9,892 China Biologic Products Holdings, Inc. shares in Q2 2021, an estimated $1.17M.
- Barclays first reported a position in China Biologic Products Holdings, Inc. in Q4 2015 and held it in 21 quarters.
- Barclays's China Biologic Products Holdings, Inc. position peaked at $1.61M in Q3 2020.
- 0 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2021.
Based on Barclays's 13F filing for Q2 2021, filed 13 Aug 2021.